Agilent announces acquisition of avida biomed, developer of high-performance ngs target enrichment workflows for cancer research

Santa clara, calif.--( business wire )--agilent technologies inc. (nyse: a) today announced the acquisition of avida biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (ngs) approaches to study cancer.
A Ratings Summary
A Quant Ranking